In fiscal year 2025, ST PHARM (237690) reported revenue of 331.7 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|
| 2025 | 331.7 billion KRW | 54.9 billion KRW | 54.6 billion KRW | [source] |
| 2024 | 273.8 billion KRW | 27.7 billion KRW | 32.5 billion KRW | [source] |
| 2023 | 285.0 billion KRW | 33.5 billion KRW | 17.5 billion KRW | [source] |
| 2022 | 249.3 billion KRW | 17.9 billion KRW | 17.5 billion KRW | [source] |
| 2021 | 165.6 billion KRW | 5.6 billion KRW | 3.4 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|
| 2025 | 776.7 billion KRW | 178.0 billion KRW | 598.7 billion KRW | [source] |
| 2024 | 712.1 billion KRW | 202.8 billion KRW | 509.3 billion KRW | [source] |
| 2023 | 661.7 billion KRW | 272.9 billion KRW | 388.8 billion KRW | [source] |
| 2022 | 555.1 billion KRW | 214.5 billion KRW | 340.7 billion KRW | [source] |
| 2021 | 494.7 billion KRW | 165.9 billion KRW | 328.8 billion KRW | [source] |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|
| 2025 | — | — | — | [source] |
| 2024 | — | — | — | [source] |
| 2023 | 1.3 billion KRW | -82.4 billion KRW | 81.4 billion KRW | [source] |
| 2022 | 7.0 billion KRW | -5.7 billion KRW | 10.8 billion KRW | [source] |
| 2021 | 7.3 billion KRW | -8.0 billion KRW | -116 million KRW | [source] |
Cash flow figures for the relevant year were not collected.
